Maya had been at her company for six years when she and her partner decided to start fertility treatment. She did what careful employees do: she read the benefits guide, called the insurer, and asked her manager, quietly, whether anyone else had navigated this. The guide mentioned "infertility services" in a single line. The insurer gave her a different answer on each of three calls. Her manager, well-meaning, had no answer at all. By the time Maya understood what her plan actually covered, she had already spent $4,000 on testing that no one had told her would count against a lifetime cap.
Maya's story is now a recruiting story. In the past decade, fertility benefits have moved from a rare perk at a handful of technology firms to a standard item in the competition for professional talent — and the companies that handle it best are discovering that the benefit is worth more than the retention numbers suggest.
From perk to expectation
The shift has a clear timeline. In 2014, Apple and Facebook made headlines by adding egg freezing to their benefits. At the time, the move was framed as a Silicon Valley curiosity. By 2019, Progyny, a benefits manager built specifically around fertility treatment, had completed an initial public offering, and Carrot Fertility, founded in 2016, was signing large employers across industries. Mercer, the consulting firm, reported in its national benefits surveys that the share of large employers offering fertility coverage rose steadily through the late 2010s and early 2020s, with coverage for IVF becoming common among employers with 500 or more workers.
The economics help explain the speed. A single IVF cycle costs $20,000 or more once medication is included, per American Society for Reproductive Medicine guidance, and many patients need more than one cycle. For an employee earning $120,000, a $40,000 bill is a third of a year's gross pay. Employers that cover it remove a barrier that otherwise forces workers to delay treatment, take on debt, or leave for a job with better coverage.
There is also a demographic logic. The average age of first-time mothers in the United States reached 27.5 in 2023, according to CDC birth data, up from 21.4 in 1970 — and among college-educated women, first births in the mid-thirties are now routine. A workforce that starts families later will need fertility care more often. The CDC estimates that about 19 percent of married women aged 15 to 44 are unable to get pregnant after one year of trying. Employers are not inventing this demand. They are finally acknowledging it.
What good coverage actually covers
Not all fertility benefits are equal, and the differences matter more than the headline. The weakest version is a small lifetime dollar cap — $10,000 or $15,000 — that covers testing and perhaps part of one cycle, then stops. The strongest version, pioneered by Progyny's "Smart Cycle" model, covers a defined number of treatment cycles rather than a dollar amount, so a patient is not penalized because her medication costs more than a colleague's. Carrot takes a different approach, giving employees a flexible fund they can spend across fertility, adoption, and related services, with coaching and navigation support included.
The distinction between a dollar cap and a cycle-based benefit is not technical fine print. It determines whether an employee can finish treatment. FertilityIQ surveys have found that many patients spend $30,000 or more in total, and a $15,000 cap leaves the hardest decisions — a second cycle, genetic testing, donor eggs — exactly where they were: on the family's credit card. Companies that advertise fertility coverage while capping it below the cost of a single full cycle are selling a headline, not a benefit.
Navigation matters as much as money: the best programs pair coverage with a guide who explains what a quote includes, which clinics have the strongest outcomes for a patient's age group, and how to appeal a denial.
The business case, tested
Skeptics inside finance departments ask the obvious question: does this pay? The honest answer is that the return is real but indirect, and companies that demand a simple payback calculation will miss it.
First, retention. Employees who use fertility benefits tend to stay. Progyny has reported that clients see strong retention among benefit users, and the logic is intuitive: a worker whose employer funded the treatment that built her family is unlikely to leave lightly. Productivity and downstream health costs point the same way: treatment involves frequent appointments, and benefits covering enough cycles to allow single-embryo transfer can reduce the costly twin and triplet pregnancies that multiple-embryo transfers risk.
Small firms face genuine budget constraints, and a benefit that costs $50,000 per user cannot be casually added to a plan covering twenty employees. That is why the market has split: large employers buy comprehensive programs, while smaller firms offer narrower versions — testing coverage, a modest fund, or discounted clinic networks through companies like Kindbody.
The counterargument, stated fairly
Critics of employer fertility benefits raise two objections worth taking seriously. The first is equity: a generous fertility benefit helps the professional workforce while doing nothing for hourly workers, gig workers, and the uninsured, who face the same prices with fewer resources. If fertility coverage becomes a perk of elite employment, it could deepen the very inequality that makes fertility care a luxury good in the first place.
The second objection is subtler: egg freezing as an employer benefit, critics argue, can read as "delay parenthood for your career, and we will help you freeze the clock" — criticism Apple and Facebook faced in 2014 that has not fully faded.
Both objections point to the same remedy: design benefits around choice, not delay, and pair them with broader access — adoption and surrogacy support alongside IVF, male-factor testing (male factors contribute to roughly a third of infertility cases, per the CDC and the American Urological Association), and eligibility for part-time and hourly staff where possible. State mandates help too: Kaiser Family Foundation tracking puts the count at about 20 states, though mandates vary sharply.
What comes next
The next phase of this market will be shaped by price data. Employers buying fertility benefits at scale are already demanding clinic-level prices and outcomes from managers like Progyny and Carrot, and they are steering employees toward higher-value clinics. That pressure, applied quietly through contracts, may do more for price transparency than any consumer website could. When a buyer covering 10,000 employees asks for a clinic's all-in cycle price and its live-birth rate by age band, the clinic answers.
For employees, the practical advice is blunt: get the benefit in writing — cycles covered, whether medication counts against the cap, whether genetic testing is included, what happens if you change jobs mid-treatment — and use the navigator if one is offered. If your employer offers nothing, ask. Benefits expand when employees name the gap.
Maya eventually got her coverage sorted out, completed two cycles, and still works at the same company. When a new hire asks about benefits, she mentions the fertility program before the gym discount — sometimes the most persuasive brand statement is a benefit that arrives exactly when a family needs it most, and covers enough to matter.
Sources: Sources cited in this article: American Society for Reproductive Medicine cost guidance; CDC birth and infertility data; Mercer national benefits surveys; Progyny and Carrot Fertility company materials; Kaiser Family Foundation state mandate tracking; FertilityIQ patient cost surveys; American Urological Association male-factor guidance.